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ABSTRACT Salmonella enterica serovars cause severe diseases in humans, such as gastroenteritis and typhoid fever. The develop-
ment of systemic disease is dependent on a type III secretion system (T3SS) encoded by Salmonella pathogenicity island-2 (SPI-
2). Translocation of effector proteins across the Salmonella-containing vacuole, via the SPI-2 T3SS, enables bacterial replication
within host cells, including macrophages. Here, we investigated the contribution of these effectors to intramacrophage replica-
tion of Salmonella enterica serovar Typhimurium using Fluorescence Dilution, a dual-fluorescence tool which allows direct
measurement of bacterial replication. Of 32 strains, each carrying single mutations in genes encoding effectors, 10 (lacking sifA,
sseJ, sopD2, sseG, sseF, srfH, sseL, spvD, cigR, or steD) were attenuated in replication in mouse bone marrow-derived macro-
phages. The replication profiles of strains combining deletions in effector genes were also investigated: a strain lacking the genes
sseG, sopD2, and srfH showed an increased replication defect compared to single-mutation strains and was very similar to SPI-2
T3SS-deficient bacteria with respect to its replication defect. This strain was substantially attenuated in virulence in vivo and yet
retained intracellular vacuole integrity and a functional SPI-2 T3SS. Moreover, this strain was capable of SPI-2 T3SS-mediated
delivery of a model antigen for major histocompatibility complex (MHC) class I-dependent T-cell activation. This work estab-
lishes a basis for the use of a poly-effector mutant strain as an attenuated vaccine carrier for delivery of heterologous antigens
directly into the cytoplasm of host cells.
IMPORTANCE Live attenuated strains of Salmonella enterica serotype Typhi have generated much interest in the search for im-
proved vaccines against typhoid fever and as vaccine vectors for the delivery of heterologous antigens. A promising vaccine can-
didate is thearoCssaV S. Typhi strain, which owes its attenuationmainly to lack of a type III secretion system (SPI-2 T3SS).
The SPI-2 T3SS is important for bacterial proliferation inside macrophages, but not all of the effectors involved in this process
have been identified. Here, we show that 10 effectors of the related strain S. Typhimurium contribute to intracellular replication
in macrophages. Moreover, we establish that a poly-effector mutant strain of S. Typhimurium can have a severe replication de-
fect andmaintain a functional SPI-2 T3SS, which can be exploited for delivery of heterologous antigens.
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Salmonella enterica serovars are Gram-negative bacteria thatcolonize a wide range of host species. In humans, Salmonella
enterica serovars Typhimurium (S. Typhimurium) and Typhi (S.
Typhi) usually cause self-limiting gastroenteritis and typhoid fe-
ver, respectively. In susceptible mouse strains, infection with S.
Typhimurium leads instead to systemic disease, providing a com-
monly used model system for the study of typhoid fever. Salmo-
nella has two functionally distinct type III secretion systems
(T3SS) encoded by Salmonella pathogenicity islands 1 and 2
(SPI-1 and -2). The SPI-1 T3SS is central to the ability of Salmo-
nella to invade nonphagocytic cells through the delivery of effector
proteins which trigger extensive actin rearrangements on the sur-
face of host cells (1). The SPI-2 T3SS, on the other hand, is acti-
vated intracellularly and is essential for bacterial replication inside
host cells (2, 3). Furthermore, the ability of Salmonella to prolif-
erate within phagocytic cells, including macrophages, is a hall-
mark of systemic disease (4). Bacterial replication occurs in a
membrane-bound compartment called the Salmonella-containing
vacuole (SCV). Effector proteins are translocated across the vac-
uolar membrane, via the SPI-2 T3SS, into the host endomem-
brane system and cytoplasm.
Intracellular bacterial growth is usually quantified by determi-
nation of net bacterial load within infected cells by counting CFU
from cell or tissue lysates plated onto medium. However, CFU
counts are the product of both replication and killing undergone
by the bacteria. Work in our laboratory based on a dual-
fluorescence reporter system, Fluorescence Dilution, permits di-
rect assessment of bacterial replication (5). In both bonemarrow-
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derived (BM) macrophages and the RAW 264.7 macrophage cell
line, the SPI-2 T3SS was shown to enable bacterial proliferation
rather than survival (5).
Despite the importance of the SPI-2 T3SS in S. Typhimurium
replication, little is known about the translocated effectors that
mediate this process. A total of 32 effectors were reported to be
translocated via the SPI-2 T3SS (6–9), although only a small num-
ber have been confirmed to be directly involved in intracellular
bacterial growth. The effectors SseF and SseG are essential for
localizing SCVs to the Golgi network in epithelial cells. Strains
lacking genes for SseF or SseG have a moderate growth defect in
RAW macrophages (10, 11) and epithelial cells (12). Another
three effectors functioning in SCV membrane dynamics, SifA,
SseJ, and SopD2, are also important for bacterial growth. Several
studies have reported a strong growth defect of a sifA mutant
strain in macrophages (13–18). This can be explained by the find-
ing that the majority of sifAmutant bacteria lose their vacuolar
membranes (15) and are killed by the microbicidal environment
of the macrophage cytosol (13). SseJ is a glycerophospholipid:
cholesterol acyltransferase (GCAT) (19, 20). Since a strain with
sifA and sseJ mutations retains its vacuolar membrane (21),
SseJ is thought to counter the effects of SifA on the SCV mem-
brane. A sseJ strain has a growth defect in RAW 264.7 cells (17)
and peritoneal macrophages (21). SopD2 also regulates SCV
membrane dynamics, although its exact function is unknown. A
decrease in the bacterial load of a sopD2 strain compared to a
wild-type strain was shown in RAW 264.7 macrophages (22), but
a second study in the same cell type did not detect a growth defect
(18). In addition, our laboratory found recently that the effector
SseL contributes to intracellular replication in macrophages (23).
A recent study of the contribution of some SPI-2 T3SS effectors to
replication found that, in RAW 264.7 macrophages, strains lack-
ing the effector genes sifB, steC, or spvB or sseK1 sseK2 sseK3 had
significantly reduced growth levels (24). In previous studies, how-
ever, intracellular growth defects were not detected in strains car-
rying deletions in these genes (17, 25, 26).
In this study, we determined the contributions of individual
effectors of the SPI-2 T3SS to intramacrophage replication of S.
Typhimurium. We found that approximately 30% of effectors
contribute to intracellular replication. Based on these results, we
combined mutations to generate a triple-mutation (sseG
sopD2srfH) strain with a replication defect similar to that of an
SPI-2 null strain. This strain retains a functional T3SS and was
used to deliver a heterologous antigen for MHC class I (MHC-I)-
dependent T-cell activation.
RESULTS
Contribution of SPI-2 T3SS effectors to replication in mouse
bonemarrow-derivedmacrophages.Todetermine the contribu-
tion of effectors of the SPI-2 T3SS to intracellular replication in
macrophages, replication of wild-type and mutant strains was as-
sessed by Fluorescence Dilution using a second-generation plas-
mid, pFCcGi, from which expression of mCherry is constitutive
and that of green fluorescent protein (GFP) is under the control of
an arabinose-inducible promoter (Fig. 1A). Bacteria carrying pF-
CcGi were initially grown in vitro in the presence of arabinose to
drive production of GFP. Upon infection of macrophages with
these bacteria, in the absence of arabinose, the preformed pool of
GFPbecomes halvedwith each bacterial cell division event. There-
fore, bacterial replication is measured by dilution of the green
fluorescence, with bacterial cells being detected on the basis of
mCherry fluorescence (Fig. 1B). Use of pFCcGi-based Fluores-
cence Dilution as a reporter of bacterial replication was validated
bymeasuring in vitro growth of bacteria. Dilution of GFP enabled
accurate measurement of bacterial replication over 6 generations
(data not shown). Moreover, there was no detectable effect on
bacterial cell division time in macrophages, in contrast to the mi-
nor increase observed for pDiGc in a previous study (5).
The replication rate of two S. Typhimurium SPI-2-T3SS null
strains,ssaV andsseB (encoding a secretion apparatus compo-
nent and translocon protein, respectively), was compared to that
of a wild-type strain in bone marrow-derived macrophages ex-
tracted from C57 BL/6 mice. At 2 h and 17 h postuptake, dilution
of GFP fluorescence in bacteria recovered frommacrophages was
analyzed by flow cytometry (Fig. 1Ci). Replication was quantified
from the geometric mean of GFP fluorescence by calculating the
fold change between the results determined at the two time points
(Fig. 1Cii). Extensive replication of wild-type S. Typhimurium
occurred in these macrophages over 17 h of infection, as illus-
trated by the shift in GFP fluorescence intensity, while replication
of SPI-2-T3SS-deficient strains was much reduced. The number
of generations undergone by the bacterial populations was de-
duced by FluorescenceDilution andwas higher than that reported
in our previous paper, which can be attributed to the presence of
pFCcGi in place of pDiGc (5). The mean rate of division of the
wild-type strain (approximately 0.3 generations/h) was 3-fold
higher than that of the two strains lacking a functional SPI-2 T3SS
(approximately 0.1 generations/h). The large difference between
the control strains (wild-type and SPI-2 T3SS null strains) in GFP
fluorescence enabled relatively subtle contributions to replication
to be detected in effector mutant strains.
Using the  Red recombinase method (27), we generated 24
single-gene deletions to obtain, together with previously con-
structed strains, a total collection of 32 SPI-2 T3SS mutant strains
representing all known effectors. Three genes for SPI-1 T3SS ef-
fectors (sopD, sptP, and avrA) were included in the study, as they
have been reported to be secreted via the SPI-2 T3SS (6, 8). The 32
mutant strains were transformed with pFCcGi, and their intra-
macrophage replication rate was analyzed (Fig. 2). In each exper-
iment, values of mean fold change in GFP fluorescence between
2 h and 17 h were calculated and normalized to that of the wild-
type strain to obtain a replication index (RI), which, for the wild-
type strain, was 1.0. The RI of 10 strains was significantly reduced
compared to that of the wild-type strain. Those 10 strains con-
tained mutations in sifA (0.29), sseJ (0.41), sopD2 (0.48), sseG
(0.40), sseF (0.50), srfH (0.48), sseL (0.72), spvD (0.61), cigR (0.68),
or steD (0.69) (Fig. 2). Displaying the strongest replication defects
among these (values below 0.5) were fivemutant strains withmu-
tations in sifA, sseJ, sopD2, sseG, and sseF that were previously
described to contribute to intramacrophage growth as assessed by
CFU counts (10, 11, 13, 15–17, 22).
Effect of cumulative mutations in genes of SPI-2 T3SS effec-
tors on replication.Nextwe determined if combining deletions in
certain genes could result in stronger replication defects. Some
effectors of the SPI-2 T3SS have similar functions or are known to
contribute to the same SPI-2-mediated process inside host cells.
Therefore, as a first approach,mutations were combined in two or
more genes related by function (Fig. 3A). Three groups were se-
lected: (i) effectors involved in SCV membrane dynamics (SifA,
SseJ, SopD2, and PipB2), based on the observed impact that the
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majority of these effectors have on replication; (ii) effectors shar-
ing E3 ubiquitin ligase activity (SspH1, SspH2, and SlrP), to ac-
count for possible redundancy in their function; and (iii) effectors
SseK1, SseK2, and SseK3, because, although their function is un-
known, their amino acid sequences bear striking similarities (26,
28), suggesting they might have similar functions. We did not
measure the replication rate of an sseF sseG double mutant, as this
has been shown previously to be indistinguishable from single
mutants in terms of virulence attenuation and intracellular pro-
liferation (29).
Three strains were constructed that carry a sifA mutation but
for which the vacuolar membrane is maintained through the
counteracting and stabilizing effect of additional mutations:
strains sifA sseJ, sifA sopD2, and sifA sopD2 pipB2 (18,
21). The three strains showed significantly less replication than the
wild-type strain (RI 0.49, 0.25, and 0.17, respectively) (Fig. 3A).
Despite the presence of a vacuolar membrane, normal replication
levels were not restored in these strains. On the other hand, none
of these strains had a greater replication defect than the strain with
the single sifAmutation (Fig. 2). Genes encoding effectors with E3
ubiquitin ligase activity were also investigated using strains carry-
ing deletions in two genes (sspH1 sspH2) or three genes (slrP
sspH1 sspH2). There was no additive effect on the replication
defect caused by additional mutations, suggesting that this family
of effectors does not contribute to intracellular replication (Fig. 2
and 3A). Likewise, combiningmutations in genes of the sseK fam-
ily (sseK1sseK2,sseK1sseK3, orsseK1sseK2sseK3) had
no significant effect on replication (Fig. 2 and 3A). This suggests
that the SseK effectors have functions other than in bacterial rep-
lication, in agreement with previous findings (26).
As a second approach, mutations in genes associated with dif-
ferent functions were combined. A strain containingmutations in
sseG and sopD2 replicated significantly less (RI  0.24) than the
corresponding single mutants (Fig. 3B) and similarly to the SPI-
2-deficient ssaV strain (RI 0.23). Introduction of a third mu-
tation to this strain resulted in strain sseG sopD2 srfH, which
had a replication defect similar to that of the double-mutation
strain (RI  0.27). The replication defect of the sseG sopD2
mutant was complemented by introduction of a plasmid carrying
wild-type alleles of both genes, followed by measurement of bac-
terial growth in bone marrow-derived macrophages at between
2 h and 17 h by CFU enumeration (see Fig. S1 in the supplemental
material).
Competitive index analysis of sseG sopD2 and sseG
sopD2srfHmutant strains.A competitive index (CI) analysis
(30) was carried out in C57 BL/6 mice following intraperitoneal
(i.p.) inoculation tomeasure the virulence attenuation of the mu-
tant strains compared to wild-type S. Typhimurium in splenic
macrophages (14). Mice were given a 1:1 mixture of the wild-type
strain and either of the mutant strains. After 3 days, bacteria were
recovered from the spleens of mice and the bacterial loads were
determined for each strain by CFU enumeration. As expected, the
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FIG 1 Use of Fluorescence Dilution to measure the impact of the SPI-2 T3SS on S. Typhimurium replication in bone marrow-derived macrophages. (A)
Expression of fluorescent proteins from the pFCcGi plasmid is constitutive formCherry and under the control of an arabinose-inducible promoter for gfp. (B)
In the absence of arabinose, levels of GFP fluorescence in preinduced bacteria become diluted as successive rounds of cell division occur. (Ci and Cii)
Macrophages were infected with S. Typhimurium strains carrying pFCcGi that were grown with arabinose prior to infection. Infections were carried out in the
absence of arabinose, and the cells were lysed at 2 h and 17 h postinoculation. Replication of recovered intracellular bacteria was measured by flow cytometry
analysis of GFP Fluorescence Dilution (n  10,000 events analyzed). (Ci) Representative histograms of GFP fluorescence in intracellular populations of
wild-type,ssaV, andsseBmutant strains. (Cii) Fold replication values were calculated from the geometricmeans of GFP fluorescence as the ratio of replication
at 17 h to replication at 2 h. Data are expressed as means standard errors of the means (SEM) of the results of five independent experiments. P values were
obtained by Student’s t test (***, P 0.001) relative to the wild-type strain results.
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ssaV mutant strain was strongly attenuated in virulence com-
pared to the wild-type strain (Fig. 4). The sseG sopD2 double-
mutation and sseG sopD2 srfH triple-mutation strains were
also attenuated in virulence, although not to the extent seen with
the ssaVmutant strain (Fig. 4).
To measure virulence attenuation following the natural route
of infection, a CI analysis was also done over 5 days following
intragastric (i.g.) inoculation. Themutant strains had lowermean
CI values after oral challenge than after inoculation by the i.p.
route (Fig. 4). Moreover, although the introduction of a third
mutation (srfH) had nomeasurable effect on replication inmac-
rophages, it resulted in CI values lower than those seen with the
double-mutation strain.
The availability of a poly-effector mutant strain of Salmonella
with a replication defect similar to that of an SPI-2 T3SS null
strain, but with a functional secretion apparatus, might provide a
means for delivery of heterologous antigens directly into the cyto-
sol of host antigen-presenting cells against the background of a
safe delivery system. Therefore, we next investigated the function-
ality of the SPI-2 T3SS in the triple-effector mutant strain.
sseGsopD2srfHmutant bacteria reside in vacuoles and
retain a functional SPI-2T3SS.SCVs acquire somecharacteristics
of late endosomes, including the presence of lysosomal glycopro-
teins such as LAMP-1 in the SCVmembrane (31). LAMP-1 label-
ing of vacuoles containing sseG sopD2 srfH bacteria was in-
distinguishable from the labeling seen with those containing wild-
type bacteria, suggesting the presence of a vacuolar membrane
around enclosing bacteria of the triple-mutation strain (Fig. 5Ai).
To confirm the integrity of vacuoles enclosing the triple mutant,
HeLa cells were infected with GFP-expressing wild-type,sifA, or
sseG sopD2 srfH bacteria for 10 h and were subsequently ex-
posed to digitonin at a concentration which permeabilizes the
plasmamembrane but not the vacuolar membrane (12), followed
by labeling with an anti-Salmonella antibody. Thus, only Salmo-
nella bacteria that were not enclosed in a vacuole were labeledwith
the antibody, allowing a distinction between intravacuolar and
cytosolic bacteria to be made. The sifAmutant strain provides a
positive control for loss of the vacuolarmembrane, as themajority
of the bacteria become cytosolic by 8 h postuptake (15). The ma-
jority (65.6%) of wild-type bacteria maintained vacuolar mem-
brane integrity, while only a small proportion (28.8%) of sifA
mutant bacteria remained enclosed within intact vacuoles
(Fig. 5Aii), in accordancewith previously published data (25). The
proportion of the triple-mutation strain within vacuoles was very
similar to that of the wild type (66.8%), confirming that the mu-
tations present in this strain do not destabilize the SCV (Fig. 5Aii).
The ability of the sseG sopD2 srfH strain to translocate
effectors via the SPI-2 T3SS into the cytosol of host cells was in-
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FIG 2 Contribution of individual SPI-2 T3SS effectors to S. Typhimurium
intracellular replication. Fluorescence Dilution analysis of the replication of S.
Typhimurium strains carrying deletions in genes of effectors of the SPI-2 T3SS
was done in bone marrow-derived macrophages over 17 h. The color code
used to group SPI-2 T3SS effectors according to their function is as follows:
SCVmembrane dynamics, green; SCV localization, yellow; cellmigration, red;
ubiquitin pathways, purple; unknown function, dark gray; actin cytoskeleton,
brown; host immune signaling, pink; SPI-1 translocated effectors, turquoise.
Data are expressed as the means SEM of the results of 3 to 30 independent
experiments (N) and were normalized to wild-type values. Statistical analysis
was performed with one-way analysis of variance (ANOVA) and a post hoc
Dunnett test (*, P 0.05; **, P 0.01) relative to the wild-type strain results.
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vestigated with strains expressing hemagglutinin (HA)-tagged
SseJ. The ssaV strain, which does not translocate effectors, was
used as a negative control. As seen by immunofluorescence mi-
croscopy, levels of SPI-2 T3SS-mediated delivery of SseJ from the
triple-mutation strain were similar to those of the wild-type strain
in bonemarrow-derivedmacrophages infected for 17 h (Fig. 5Bi).
Translocation of a second SPI-2 T3SS effector, SseF, was also con-
firmed inmacrophages (see Fig. S2 in the supplemental material).
Flow cytometry analysis of infected cells was also done to quantify
the levels of translocated SseJ. Bone marrow-derived macro-
phages or HeLa cells were infected for 17 h or 14 h, respectively,
and labeled with an antibody against the translocatedHA epitope.
Similar amounts of SseJ were translocated by the sseG sopD2
srfH and the wild-type strains in both cell types (Fig. 5Bii).
T-cell activation following SPI-2 T3SS-mediated antigen de-
livery. We next tested whether a heterologous antigen produced
in the sseG sopD2 srfH strain could be delivered into the cy-
tosol of dendritic cells (DC) through the SPI-2 T3SS and pre-
sented by MHC-I molecules (Fig. 6). Bone marrow-derived den-
dritic cells extracted from C57 BL/6 mice were infected with wild-
type, ssaV, or sseG sopD2 srfH strains harboring a plasmid
expressing the T-cell ovalbumin-derived SIINFEKL antigen fused
to SseJ under the control of the sseA promoter (p3631) (32).Wild-
type S. Typhimurium that did not carry the plasmid was used as a
negative control. Purified SIINFEKL peptide added to cells in-
fected with the same strain was included as a positive control.
Following the killing of extracellular bacteria with gentamicin,
infected cells were incubated for 22 h with the murine B3Z T-cell
hybridoma, which is specific for SIINFEKL in the context of
H-2Kb and which, upon activation, expresses the lacZ reporter
gene (33).-Galactosidase activity was used as ameasure of T-cell
stimulation in the assay. Cells infectedwith the wild-type orsseG
sopD2 srfH strain expressing the antigen showed a significant
increase in-galactosidase activity (Fig. 6) similar to that obtained
with the positive control. On the other hand, the level of
-galactosidase activity following infection with the ssaV mu-
tant carrying p3631 was similar to the background levels obtained
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FIG 4 Competitive index (CI) analysis of sseG sopD2 and sseG sopD2
srfH strains. C57 BL/6 mice were inoculated by intraperitoneal (i.p.) injec-
tion (5 105 CFU) or intragastric (i.g.) inoculation (3 108 CFU) with equal
amounts of wild-type and ssaV, sseG sopD2, or sseG sopD2 srfHmu-
tant strains. Bacteria were recovered from infected spleens 3 days (i.p.) or
5 days (i.g.) postinoculation. CI values were calculated as the ratio of wild-type
strain to mutant strain recovered (Output) divided by the ratio of wild-type
strain to mutant strain present in the inoculum (Input). The scatter plot dis-
plays values obtained for individual mice, and the means are indicated (long
horizontal lines). P values obtained by Student’s t test confirmed that all CI
values are statistically different from 1.0 (**, P 0.01).
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withwild-type bacteria lacking p3631. This shows that T-cell stim-
ulation is dependent on SPI-2 T3SS-mediated translocation of the
SseJ-SIINFEKL fusion. Therefore, we conclude that despite the
strong virulence attenuation caused by loss of sseG, sopD2, and
srfH, this strain retains the ability to deliver a modified effector
into the cytosol of dendritic cells and to stimulate T-cell activity
following MHC-I antigen presentation.
DISCUSSION
In this work, we have compared the intracellular replication char-
acteristics of 32 mutant strains of S. Typhimurium lacking indi-
vidual effectors of the SPI-2 T3SS. Three of these mutations were
then combined to make a triple-mutation strain with strong in-
tramacrophage replication and virulence defects. Despite this at-
tenuated phenotype, the strain displayed SPI-2 T3SS-dependent
delivery of a model epitope into the cytosol of dendritic cells,
which stimulated CD8-T-cell responses. This study was influ-
enced by the results of clinical trials using the S. Typhi strain
M01ZH09 aroC ssaV, which has shown considerable promise
as a potential single-oral-dose vaccine against typhoid (34–39).
This strain owes its attenuation mostly to SPI-2 T3SS deficiency,
which results in the reduction of replication of the strain in host
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FIG 5 Vacuolar integrity and SPI-2 T3SS functionality in intracellular S. Typhimurium sseG sopD2 srfH. (Ai and Aii) Intravacuolar localization of sseG
sopD2 srfH in epithelial cells. (Ai) Confocal microscopy images of LAMP-1 labeling of HeLa cells infected with S. Typhimurium wild-type, ssaV, or sseG
sopD2 srfH strains for 14 h. Cells were fixed and immunolabeled with anti-Salmonella (green in merged images) and anti-LAMP-1 (red in merged images)
antibodies. Scale bars represent 5 m. (Aii) HeLa cells infected for 10 h with GFP-expressing S. Typhimurium wild-type, sifA, or sseG sopD2 srfH strains
were treated with digitonin to selectively permeabilize the plasma membrane and labeled with anti-Salmonella antibody. Percentages of intravacuolar and
cytosolic bacteria were calculated based on differential labeling. (Bi and Bii) Translocation of an SPI-2 T3SS effector from S. TyphimuriumsseGsopD2srfH.
Bone marrow-derived macrophages or HeLa cells were infected for 17 h or 14 h, respectively, with the indicated S. Typhimurium strains expressing HA-tagged
SseJ from the plasmid pWSK29. (Bi) Confocal microscopy images of SseJ-2HA translocation in macrophages. Cells were fixed and immunolabeled with
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SseJ-2HA by flow cytometry analysis of infected cells immunolabeled with anti-Salmonella and anti-HA antibodies. Data were calculated from the geometric
means of fluorescence associated with anti-HA labeling and are expressed asmeans SEMof the results of three independent experiments. ThessaV strain was
included as a negative control for effector translocation in each experiment (P 0.001). P values were obtained by Student’s t test (*, P 0.05) relative to the
wild-type (WT) strain results.
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cells and systemic spread (36). It might be feasible to achieve a
similar profile of attenuation and immunogenicity through mu-
tation of key effector genes in which the T3SS remains intact and
competent for delivery ofmodified effectors into host cells. Such a
strain could be exploited for cytosolic delivery of heterologous
antigens in antigen-presenting cells to generate immunity against
both Salmonella and an unrelated pathogen.
Others have reported the use of the Salmonella SPI-2 T3SS for
delivery of heterologous antigens (40–42) and anticancer agents
(43) directly into the cytoplasm of host cells. Those studies were
successful in showing good levels of MHC-I presentation and
CD8 T-cell recognition. Previous studies have also focused on
comparing the efficiencies of various in vivo-activated promoters
and effector fusions of the SPI-2 T3SS in driving heterologous
antigen expression and delivery from an attenuated purD htrA
double-mutation strain as an attenuated carrier (32, 42). Antigens
fused to SseJ were identified as eliciting a potent T-cell response
(32).
Our study represents a comprehensive analysis of replication
defects associatedwith strains lacking individual SPI-2 T3SS effec-
tors in which mutant strains were simultaneously analyzed under
the same conditions. A previous study tested the intracellular
growth of a smaller group of effector mutant strains, comprising
11 single deletions (sifA, sifB, sseF, sseG, srfH, sspH2,
slrP, steA, steC, gogB, and spvB), as well as strains sseF
sseG and sseK1 sseK2 sseK3 (24). In RAW 264.7 macro-
phages, over 24 h, CFU counts showed a growth defect of sifA,
sifB, steC, spvB, and sseK1 sseK2 sseK3 mutant strains,
although strains carrying deletions in sseF or sseG or both sseF and
sseG were not significantly attenuated in those assays (24). With
the exception of the sifA strain results, these findings are not in
accord with our results or those of other studies (10, 11, 17, 25, 26,
44). It is possible that the discrepancies might be explained by
differences in the types of macrophage that were used, as it was
already reported that the extent and nature of replication of Sal-
monella are different in the macrophage-like cell line RAW264.7
or in primary bone marrow-derived macrophages (5). In our
study, a significant replication defect was detected for 10 strains,
indicating that sifA, sseJ, sopD2, sseF, sseG, and srfH are largely
responsible for SPI-2 T3SS-mediated intracellular replication and
that sseL, spvD, cigR, and steD also contribute to this process. The
use of Fluorescence Dilution with the sifAmutant bacteria shows
that its growth defect is not just the consequence of bacterial kill-
ing in the cytosol of macrophages, as a result of vacuolar loss (13),
but that bacteria remaining inside SCVs undergo diminished rep-
lication. Moreover, the effect of deleting srfH, spvD, cigR, or steD
on replication had not been previously demonstrated. SrfH is in-
volved in migration of infected cells and is required for long-term
systemic infection, but CFU analysis inmacrophages had not pre-
viously revealed a function for SrfH in intracellular growth (45,
46). The three remaining effectors contributing to intracellular
replication (SpvD, CigR, and SteD) were identified recently using
mass spectrometry of secreted proteins (47), and their function is
not yet known. Among the effectors with known function, those
affecting replication appear to be involvedmainly inmaintenance
of the SCV membrane and the localization of the SCV in the cell.
This is not surprising, as fusion of vesicles with the SCV is likely to
provide a source of nutrients for the dividing bacteria. Similarly,
the spatial localization of vacuoles might facilitate their interac-
tions with components of the host cell that contribute to bacterial
replication.
The combined deletion of sseG, sopD2, and srfH in S. Typhi-
murium was sufficient to generate a strain that showed a strong
replication defect in macrophages and virulence attenuation in
mice. However, its level of virulence was still greater than that of
the ssaV SPI-2 null mutant, which indicates that additional mu-
tations may need to be made to further reduce its virulence. Such
mutations could be selected on the basis of CI tests involving the
remaining 22 effector mutants. Strains that do not have replica-
tion defects in macrophages, but which are attenuated for viru-
lence, might carry mutations in genes whose products are in-
volved in immune suppression, host cell cytotoxicity, and
bacterial spread. Indeed, Salmonella has been reported to interfere
with host MHC-I and MHC-II antigen presentation (48–50) as
well as to inhibit T-cell proliferation (51, 52). Mutation of all
effector geneswould be predicted to generate a strainwith levels of
virulence attenuation comparable to that of the ssaV mutant
while retaining a functional secretion apparatus.However, besides
the technical challenge of producing a strain with 32 gene dele-
tions, it is possible that not all mutations would contribute to the
optimal efficacy of a live attenuated vaccine. Indeed, at least one
effector (SteC) has been reported to attenuate virulence (53).
Therefore, some effectors might have activities that could be use-
ful to preserve in a vaccine. Further work on functional analysis of
effectors is necessary to achieve the right balance between suffi-
cient attenuation for safe administration and strong immunoge-
nicity (54). Regarding the applicability of this knowledge to ty-
phoid vaccine design, it is important to bear inmind that not all S.
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FIG 6 T-cell stimulation by SPI-2-mediated delivery of a model antigen from
S. Typhimurium sseG sopD2 srfH. Bone marrow-derived dendritic cells
(BM-DC) were infected with indicated S. Typhimurium strains harboring the
plasmid pWSK29 PsseA sseJ::OVA::HA (p3631). Cells infected with wild-type S.
Typhimurium, in the absence of the plasmid, were used as a negative control.
Stimulationwith the SIINFEKLpeptidewas used as a positive control. Infected
cells were cocultured for 22 h with B3Z T-cell hybridoma reporter cells
(ratio of BM-DC to T cells of 1:4) followed by a 6-h incubation in the presence
of the -galactosidase substrate chlorophenyl red -galactopyranoside.
-Galactosidase activity was measured colormetrically by the amount of sub-
strate converted at 595 nm. Results were normalized to values obtained with
the negative control and are expressed as means SEM of the results of four
independent experiments, each performed in triplicate.P valueswere obtained
by Student’s t test relative to thewild-type negative-control results (*,P 0.05;
**, P 0.01).
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Typhimurium SPI-2 T3SS effectors are present in S. Typhi or S.
Paratyphi (55). The present study nonetheless establishes proof of
concept that a poly-effector mutant strain of Salmonella can have
a severe replication defect and still be able to deliver modified
heterologous antigen-containing effectors into the host cell and in
sufficient amounts to generate an MHC-I-dependent T-cell re-
sponse.
MATERIALS & METHODS
Bacterial strains and growth conditions. S. Typhimurium strains used in
this study are listed in Table S1 in the supplemental material. Bacteria
were routinely grown in LB (Lennox L. Broth base), and, where appro-
priate, growth medium was supplemented with the following anti-
biotics at the indicated concentrations: carbenicillin (50 g/ml), kana-
mycin (50 g/ml), and chloramphenicol (35 g/ml). For Fluorescence
Dilution assays, bacterial strains carrying pFCcGi were grown in mag-
nesium minimal medium (Mg-MES) containing 170 mM 2-(N-
morpholino)ethanesulfonic acid (MES) at pH 5.0, 5 mM KCl, 7.5 mM
(NH4)2SO4, 0.5 mM K2SO4, 1 mM KH2PO4, 10 mM MgCl2, 38 mM
glycerol, and 0.1% Casamino Acids (56), supplemented with 50 g/ml
carbenicillin and 0.2% L-arabinose to allow production of GFP.
Bacterial mutagenesis. S. Typhimurium 12023 mutant strains were
constructed using a one-step  Red recombinase chromosomal inactiva-
tion system (27). Primer sequences designed formutagenesis and for con-
firmation by PCR of the deletion genotype are listed in Table S2 in the
supplemental material. Mutagenesis primers were designed to amplify an
antibiotic resistance cassette and contained a 40-nucleotide sequence ho-
mologous to regions flanking the target gene on the chromosome.
Plasmids. Plasmids used in this study are listed in Table S1 in the
supplemental material. For bacterial mutagenesis, plasmid pKD3 or
pKD4 was used as the template to amplify the chloramphenicol or kana-
mycin resistance gene, respectively, and amplification reaction products
were electroporated into pKD46-containing bacteria expressing the Red
recombinase enzyme (27). Clean deletions by excision of antibiotic resis-
tance cassettes were generated with FLP recombinase expressed from
pCP20 (27). For the construction of pFCcGi, mCherry was amplified
from pmCherry using primers C1 and C2 (see Table S2 in the supplemen-
tal material) and introduced into the vector pFPV25.1, previously cleaved
with XbaI and HindIII to release gfpmut3a. The vector was subsequently
cleaved with EcoRV to allow insertion of a PBAD::gfpmut3a promoter
fusion. This fragment was obtained frompGFP-arabinose (pGara), which
was digested with ClaI and HindIII. pFCcGi was electroporated into S.
Typhimurium 12023 wild-type andmutant strains. The plasmid pACYC-
sseG, carrying the sseG gene under the control of the tetracycline resistance
(Tetr) promoter of pACYC184 (12), was used to construct pACYCsseG/
sopD2. The primers pACYC-SopD2 FW and pACYC-SopD2 REV (see
Table S2 in the supplementalmaterial) were used to amplify sopD2 from S.
Typhimurium 12023, introducing BamHI and SalI restriction sites flank-
ing the gene. The fragment was introduced immediately downstream of
sseG on the vector, also under the control of the Tetr promoter.
Cell culture.RAW264.7murinemacrophage-like cells andHeLa cells
were grown in Dulbecco’s modified Eagle medium (DMEM; PAA Labo-
ratories) supplemented with 10% (vol/vol) heat-inactivated fetal calf se-
rum (FCS; PAA Laboratories) and 2 mM glutamine at 37°C in 5% (vol/
vol) CO2. The B3Z CD8 T-cell hybridoma was grown in RPMI 1640
(Invitrogen) supplemented with 10% FCS, 2 mM glutamine, and 0.05 M
-mercaptoethanol at 37°C in 5% CO2. Primary bone marrow-derived
macrophages or dendritic cells were extracted from C57 BL/6 mice
(Charles River). Cells were recovered from mice tibias and femurs (57).
Red blood cells were lysed with 0.83% NH4Cl, and the remaining undif-
ferentiated bone marrow cells were cultured at 37°C in 5% CO2 in com-
plete medium consisting of RPMI 1640 supplemented with 10% FCS,
2 mM glutamine, 1 mM sodium pyruvate, 10 mM HEPES, 0.05 M
-mercaptoethanol, 100 U/ml penicillin-streptomycin, and 20% (vol/
vol) L929-cell conditioned medium (National Institute of Medical Re-
search) or 20 ng/ml granulocyte-macrophage colony-stimulating factor
(GM-CSF) (Sigma-Aldrich) for macrophage or dendritic cell differentia-
tion, respectively. After 3 days of culture, further fresh complete medium
was added to the growing cells. On day 6, cells were washed and seeded in
completemediumwithout antibiotic and incubated overnight before bac-
terial challenge.
Bacterial replication assay in macrophages by Fluorescence Dilu-
tion. Bone marrow-derived macrophages were seeded at a density of 1
106 cells perwell in 6-well plates 24 h prior to infection.Macrophageswere
infected at a multiplicity of infection (MOI) of approximately 10:1 with
bacterial strains carrying pFCcGi that were grown to stationary phase and
opsonized as previously described (15). Plates were centrifuged at 110 g
for 5min and incubated at 37°C in 5%CO2 for 25min. Cells were washed
and incubated for a further 1 h with medium containing 100 g/ml gen-
tamicin to kill extracellular bacteria. This was replaced withmedium con-
taining 20 g/ml gentamicin for the remainder of the experiment. No
antibiotic selection was necessary for maintenance of the pFCcGi plasmid
during infection assays. At specific time points, cells were washed and
lysed with 0.1% (vol/vol) Triton X-100–phosphate-buffered saline (PBS)
to release intracellular bacteria. Cell lysateswere pelleted at 13,000 g and
resuspended in PBS solution. Fluorescence levels of the recovered bacteria
were analyzed by flow cytometry. For each sample, 10,000 bacterial events
were acquired on an LSR II flow cytometer (BD) or an LSR Fortessa flow
cytometer (BD) using FACSDiva software. GFP and mCherry fluores-
cence intensities were detected at 525/50 nm and 610/20 nm, respectively.
Data were analyzed with FlowJo Software version 8.1.1 (Treestar). To
analyze GFP Fluorescence Dilution, bacteria were gated on an mCherry-
positive signal. Replication was measured as the fold change in the geo-
metric mean of GFP fluorescence intensity between two time points.
Bacterial growth assay of CFU. Bone marrow-derived macrophages
were seeded at a density of 2  105 in 24-well plates and infected with
bacterial strains as described above. Upon cell lysis at selected time points,
CFU numbers were determined by plating serial dilutions of the lysate on
LB agar. Bacterial growth was measured as the fold change in CFU/ml
between two time points.
Competitive infections. Infection studies were carried out with 6-to-
8-week-old female C57BL/6 mice (Charles River). Groups of 4 mice were
inoculated intraperitoneally (i.p.) or intragastrically (i.g.) with 0.2 ml of
bacteria suspended in PBS solution. The bacteria inoculum was 5 
104 CFU (i.p.) or 3 108 CFU (i.g.) of combined S. Typhimurium wild-
type and mutant strains (2.5 104 [i.p.] or 1.5 108 [i.g.] of each strain,
at a ratio of 1:1). The CFU of each strain in the inoculum (input) was
quantified by plating dilution series on LB agar and using antibiotic resis-
tance to distinguish between strains.Micewere sacrificed after 3 days (i.p.)
or 5 days (i.g.), and dilution series of spleen lysates were plated on LB agar
for enumeration of CFU (output), using antibiotic resistance to differen-
tiate strains. Values for competitive infections (CI) were calculated as the
ratio of mutant to wild type in the output divided by that in the input.
Immunofluorescence microscopy and antibodies. Bone marrow-
derived macrophages or RAW 264.7 macrophages were seeded onto glass
coverslips in 24-well plates at a density of 1  105 cells per well and
infected as described above. HeLa cells were seeded onto glass coverslips
in 24-well plates at a density of 5  104 cells per well at 24 h before
infection. To induce bacterial invasion, bacterial cultures were diluted
1:33 in fresh LBmedium and incubated at 37°C until an optical density at
600 nm (OD600) of 1.5 to 2.0 was reached. Bacteria were diluted in warm
Earl’s balanced salt solution (EBSS; Invitrogen) and added to cell mono-
layers at anMOI of approximately 50. Invasionwas allowed to proceed for
15 min at 37°C in 5% CO2 followed by incubation of the cells with
100 g/ml gentamicin for 1 h under the same conditions. The concentra-
tion of gentamicin was subsequently reduced to 20g/ml for the remain-
der of the experiment. At selected times, cell monolayers were washed,
fixed using 4% (wt/vol) paraformaldehyde (PFA)-PBS for 15min at 25°C,
and quenched with 10 mM NH4Cl. Cells were permeabilized with 0.1%
(wt/vol) saponin and labeled with antibodies before observation using a
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confocal laser scanning microscope (Zeiss Axiovert LSM510). For quan-
tification of intravacuolar bacteria, cells were permeabilized with 15 to
20 g/ml digitonin for 1 min prior to antibody labeling.
Quantification of effector translocation.HeLa cells or bonemarrow-
derived macrophages were seeded onto 6-well plates at a density of 2.5
105 or 1  106, respectively, and infected with strains expressing a HA
epitope-tagged effector as described above. At specific time points, cells
were washed and detached from the plate by using 0.05% (wt/vol) trypsin
for HeLa cells or by scraping the macrophages. Recovered cells were pel-
leted at 200 g for 5 min and resuspended in 3% (wt/vol) PFA–PBS for
15 min at 25°C. Cells in suspension were permeabilized in 0.1% (vol/vol)
Triton X-100–PBS or 0.1% (wt/vol) saponin–PBS for HeLa cells or mac-
rophages, respectively, for 10 min and labeled with primary antibody for
1 h and secondary antibody for 30min in solutions containing 10% horse
serum–PBS. Flow cytometry detection of the translocated epitope-tagged
effector was done on a two-laser, four-color FACSCalibur flow cytometer
(BD Biosciences). For each sample, at least 10,000 cells were analyzed.
Collected data were analyzed with FlowJo software version 8.1.1 (Treestar).
Antibodies. Anti-salmonella goat polyclonal antibody CSA-1
(Kirkegaard and Perry Laboratories) was diluted at 1:200 (immunofluo-
rescence microscopy) or 1:400 (flow cytometry). Anti-HA mouse mono-
clonal antibody HA.11 (Covance) was diluted at 1:200 (immunofluores-
cence microscopy) or 1:400 (flow cytometry). Anti-LAMP-1 mouse
monoclonal antibody H4A3 (Developmental Studies Hybridoma Bank)
was diluted at 1:200 for immunofluorescence microscopy. Anti-HA rat
monoclonal antibody 3F10 (Roche) was diluted at 1:400 for flow cytom-
etry. Donkey monoclonal anti-goat Alexa 488- or Alexa 555- and anti-
mouse Alexa 555- or Alexa 647-conjugated secondary antibodies (Invit-
rogen) were used at a dilution of 1:400 for immunofluorescence
microscopy and flow cytometry.
T-cell stimulation. Bone marrow-derived dendritic cells (BM-DC)
were seeded at a density of 2 105 in 24-well plates and infected at anMOI
of 25 or 100 for wild-type or mutant strains, respectively. Infections were
carried out as described above for primary macrophages. Infection with
the wild-type S. Typhimurium vector, with or without stimulation with
1 M SIINFEKL peptide, was used as a positive or negative control, re-
spectively. Following killing of extracellular bacteria with medium con-
taining 100g/ml gentamicin, B3Z cells expressing the lacZ reporter gene
under the control of the NFAT enhancer (33) were added to wells and
cocultured for 22 h at a BM-DC/T-cell ratio of 1:8 in medium containing
20 g/ml gentamicin. Cells were centrifuged at maximal speed for 5 min
prior to the addition of 100l substrate solution containing a lysing agent
(0.15 mM chlorophenyl red -galactopyranoside–0.5% [vol/vol] Non-
idet P-40–PBS). Following incubation for 6 h at 37°C, absorbance was
determined at 595 nm.
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